Neuroscience antibodies and assays market seen reaching $9.83 billion by 2030

The Business Research Company says the neuroscience antibodies and assays market is set to expand from $5.76 billion in 2026 to $9.83 billion by 2030, driven by rising neurological disease rates, research spending and demand for automated diagnostic tools. North America led the market in 2025, while the report points to fast growth across Asia-Pacific, Europe and other regions.

Why it matters: - Rising neurological disease rates are pushing demand for tools that help researchers and clinicians detect, analyze and monitor biomarkers tied to disorders such as Alzheimer’s and Parkinson’s disease. - The market’s projected jump to $9.83 billion by 2030 signals continued investment in neuroscience research, diagnostics and drug discovery. - Growing use of automated and multiplex assay systems could improve speed, sensitivity and reproducibility in neurological studies.

What happened: - The Business Research Company released a market intelligence report on neuroscience antibodies and assays on August 19, 2026. - The market is projected to rise from $5.03 billion in 2025 to $5.76 billion in 2026, a 14.5% increase. - The report forecasts the market will reach $9.83 billion by 2030, at a 14.3% compound annual growth rate. - North America led the market in 2025 by size. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa.

The details: - Market growth in the historical period is tied to rising neurological disorders, more funding for neuroscience research, broader use of immunoassays in diagnostics, better laboratory instrumentation and expansion of academic neuroscience programs. - Future growth is linked to higher investment in neurodegenerative disease research, demand for personalized diagnostic tools in neurology, more drug discovery activity, wider adoption of automated assay platforms and greater focus on early disease detection. - Key trends include higher use of high-specificity antibody reagents, multiplex assay systems, automation in neuroscience labs, biomarker-based neurological studies and stronger emphasis on assay reproducibility and sensitivity. - The report says neuroscience antibodies and assays help study the development, structure, function, disorders and degeneration of the nervous system. - The report describes antibodies and assays as diagnostic tests based on antigen-antibody interactions that are used in neuroscience research and clinical diagnosis. - The free sample report is available here. - The full report is available here.

Between the lines: - The growth story is less about one product category and more about a broader shift toward earlier, more precise neurological testing. - Aging populations are a major demand driver because they increase the prevalence of age-related conditions that require biomarker detection and monitoring. - The report’s emphasis on automation and reproducibility suggests the market is moving toward higher-throughput research workflows and more standardized assay performance.

What's next: - The report expects deeper adoption of automated assay platforms and biomarker-based studies as neurodegenerative research expands. - The company says its 2026 reports add market attractiveness scoring, TAM analysis, company scoring matrices, Excel-based forecasting dashboards and market hotspot infographics. - The market will likely continue to track funding levels, disease prevalence and technology adoption in neuroscience labs.

The bottom line: - Neuroscience antibodies and assays are moving from a niche research input to a core enabling market for neurological diagnosis and drug discovery.